Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epileptologist-Driven Treatment for Anxiety and Depression in Epilepsy
NCT03522987Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Escitalopram oxalate oral solution in anxiety disorder, major depressive disorder (MDD), sponsored by Wake Forest University Health Sciences. Planned start May 2018; status: withdrawn.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03522987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522987.